Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or ...

With today’s announcement, and through a variety of optimization efforts across Kite’s global CAR T-cell therapy manufacturing network, Kite estimates network capacity will be increased by 50% ...

Kite, a Gilead company GLD, announced that the Food & Drug Administration granted accelerated approval to Tecartus, a CAR T cell therapy for the treatment of adult patients with mantle cell lymphoma.

Gilead’s Kite Pharma has expanded its CAR-T agreement with MaxCyte. The revised deal gives Kite the chance to apply MaxCyte’s transfection technology to up to 10 targets. Kite first struck a ...

Kite’s CAR-T cancer therapy shows strong results as company races to win FDA approval. By Associated Press Feb. 28, 2017. Reprints. Kite Pharma is racing to get the first FDA approval of an ...

On the back of positive data presented at the recently concluded ASH meeting, Kite filed for approval of KTE-X19 in mantle cell lymphoma. The company currently markets another CAR-T, Yescarta, for ...

Kite Pharma's CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with an aggressive form of lymphoma, the company said Tuesday.

Kite Pharma and Cell Design Labs said today they will partner to develop next-generation, precision-controlled chimeric antigen receptor (CAR) T-cell immunotherapy candidates using Cell Design ...

Kite Pharma and its hotly anticipated CAR-T med nabbed an $11.9 billion buyout offer from Gilead Sciences, which has been shopping for oncology assets to diversify away from its flagging hepatitis.

Kite, a Gilead unit, announced Tuesday afternoon that it has hired Cindy Perettie as EVP. In the position, Perettie will oversee the CAR-T unit’s cell therapy business, effective May 30. Most recently ...

A new patent issued to Kite Pharma—now owned by Gilead—lays out a strict protocol for priming patients for engineered chimeric antigen receptors for T-cell (CAR-T) treatments. The patent, US ...

Kite, a Gilead Company, today announced the U.S. Food and Drug Administration has approved commercial production at the company's new CAR T-cell therapy manufacturing facility in Frederick, Maryland.